Literature DB >> 19127594

Urinary cysteinyl leukotriene E(4) is associated with increased risk for pain and acute chest syndrome in adults with sickle cell disease.

Joshua J Field1, James Krings, Nicole L White, Yan Yan, Morey A Blinder, Robert C Strunk, Michael R Debaun.   

Abstract

Leukotriene E(4) (LTE(4)) levels are associated with rate of pain episodes in children with sickle cell disease (SCD). Because complications of SCD manifest differently in adults than children, we examined a cohort of adults with SCD to determine the relationship between baseline LTE(4) and SCD-related morbidity. Baseline LTE(4) levels were associated with increased rates of pain and acute chest syndrome (ACS) episodes, when those with LTE(4) values in the highest tertile were compared with those in the lowest tertile (pain: risk ratio 7.1, 95% CI 1.8-27.5, P = 0.005; ACS: risk ratio 12.2, 95% CI 2.1-69.8, P = 0.005).

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19127594     DOI: 10.1002/ajh.21348

Source DB:  PubMed          Journal:  Am J Hematol        ISSN: 0361-8609            Impact factor:   10.047


  8 in total

Review 1.  Asthma morbidity and treatment in children with sickle cell disease.

Authors:  Samuel O Anim; Robert C Strunk; Michael R DeBaun
Journal:  Expert Rev Respir Med       Date:  2011-10       Impact factor: 3.772

2.  Recurrent, severe wheezing is associated with morbidity and mortality in adults with sickle cell disease.

Authors:  Robyn T Cohen; Anusha Madadi; Morey A Blinder; Michael R DeBaun; Robert C Strunk; Joshua J Field
Journal:  Am J Hematol       Date:  2011-08-02       Impact factor: 10.047

Review 3.  Inflammatory targets of therapy in sickle cell disease.

Authors:  Amma Owusu-Ansah; Chibueze A Ihunnah; Aisha L Walker; Solomon F Ofori-Acquah
Journal:  Transl Res       Date:  2015-07-11       Impact factor: 7.012

4.  Phase 2 trial of montelukast for prevention of pain in sickle cell disease.

Authors:  Joshua J Field; Adetola Kassim; Amanda Brandow; Stephen H Embury; Neil Matsui; Karina Wilkerson; Valencia Bryant; Liyun Zhang; Pippa Simpson; Michael R DeBaun
Journal:  Blood Adv       Date:  2020-03-24

5.  Advances in new drug therapies for the management of sickle cell disease.

Authors:  Kenneth I Ataga; Payal C Desai
Journal:  Expert Opin Orphan Drugs       Date:  2018-05-14       Impact factor: 0.694

6.  Asthma in sickle cell disease: implications for treatment.

Authors:  Kathryn Blake; John Lima
Journal:  Anemia       Date:  2011-03-03

Review 7.  Role of biomarkers in understanding and treating children with asthma: towards personalized care.

Authors:  Jason E Lang; Kathryn V Blake
Journal:  Pharmgenomics Pers Med       Date:  2013-08-21

Review 8.  Asthma management in sickle cell disease.

Authors:  Esteban Gomez; Claudia R Morris
Journal:  Biomed Res Int       Date:  2013-11-10       Impact factor: 3.411

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.